Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
1. A method for reducing body weight of a human being in need thereof comprising administering to the human being a once weekly therapeutic effective amount of a pharmaceutical dosage formulation comprising SEQ ID NO: 1 for at least 12 weeks.
2. The method of claim 1 , wherein the method induces liver fat loss.
3. The method of claim 1 , wherein the method is a treatment for blood glucose control.
4. The method of claim 1 , wherein the method does not comprise a treatment initiation phase to titrate a therapeutic dose of the pharmaceutical dosage formulation.
5. The method of claim 1 , wherein the method is an adjunct treatment with diet and/or exercise.
6. The method of claim 1 wherein the pharmaceutical dosage is administered on about days 1, 8, 15, 22, 29, and 36.
7. The method of claim 1 , wherein the pharmaceutical dosage formulation is administered subcutaneously.
8. The method of claim 1 , wherein the pharmaceutical dosage is an aqueous formulation comprising one or more of polysorbate 20, arginine, or mannitol.
9. The method of claim 1 , wherein the pharmaceutical dosage formulation comprises about 0.025-0.075% (w/w) polysorbate 20, about 0.2-0.5% (w/w) arginine, about 3-6% (w/w) mannitol in deionized water (pH 7.7±0.1); optionally about 0.050% (w/w) polysorbate 20, about 0.348% (w/w) arginine, about 4.260% (w/w) mannitol in deionized water (pH 7.7±0.1).
10. The method of claim 1 , wherein the weight of the human being is reduced by at least 5% from baseline at week 12.
11. A method for reducing body weight of a human being with a body mass index (BMI kg/m2) of at least 25 comprising administering to the human being a once weekly therapeutic effective amount of a pharmaceutical dosage formulation comprising SEQ ID NO: 1, wherein the weight of the human being is reduced by at least 5% from baseline at week 12.
12. The method of claim 11 , wherein the weight of the human being is reduced by at least 6% from baseline at week 12; by at least 7% from baseline at week 12; by at least 8% from baseline at week 12; by at least 9% from baseline at week 12 or by at by at least 10% from baseline at week 12.
13. The method of claim 11 , wherein the treatment is an adjunct treatment with increased physical activity and/or a reduced calorie diet.
14. The method of claim 11 , wherein the treatment is not in combination with increased physical activity and/or a reduced calorie diet.
15. The method of claim 11 , wherein the BMI of the human being is at least 30 kg/m2.
16. The method of claim 11 , wherein the human being at week 0 is non-diabetic.
17. The method of claim 11 , wherein the pharmaceutical dosage formulation is administered subcutaneously to the human being.
18. The method of claim 11 , wherein the pharmaceutical dosage formulation is administered to the human being once per week for at least six weeks and results in at least about 3% whole-body weight loss.
19. The method of claim 11 , wherein liver fat is reduced.